{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:18:51Z","timestamp":1784974731903,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Bone-modifying agents (BMA) are key components in the management of cancer patients with bone metastasis. Despite their clinical benefits, the use of BMA is associated with dental adverse events (AEs) including medication-related osteonecrosis of the jaw (MRONJ). This study investigated the frequency of dental surveillance before BMA treatment and the prevalence of dental AEs including MRONJ, after BMA treatment in patients with bone metastasis from breast and prostate cancer using data from the national health insurance system.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data, including age, cancer diagnosis, administered BMA, and dental AEs during cancer treatment, of patients with bone metastasis from breast and prostate cancer who received at least one infusion of BMA between 2007 and 2019 were extracted from the Korean National Health Insurance Service (KNHIS) dataset.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 15,357 patients who received BMA, 1,706 patients (11.1%) underwent dental check-ups before BMA treatment. The proportion of patients receiving dental check-up increased from 4.4% in 2007 to 16.7% in 2019. Referral to dentists for a dental check-up was more active in clinics\/primary hospitals than general\/tertiary hospitals, and medical doctors and urologists actively consulted to dentists than general surgeons, regardless of the patient\u2019s health insurance status. After BMA treatment, 508 patients (3.8%) developed dental AEs, including abscess (42.9%), acute periodontitis (29.7%), acute pericoronitis (14.9%), and MRONJ (12.5% of dental AEs cases, 0.5% of total BMA treated patients).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Considering the long treatment period in patients with metastatic cancer, coordination between dentists and oncologists is necessary to ensure appropriate dental management before the initiation of BMA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-024-10859-7","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T20:25:04Z","timestamp":1712089504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The trend of dental check-up and prevalence of dental complications following the use of bone modifying agents in patients with metastatic breast and prostate cancer: analysis of data from the Korean National Health Insurance Service"],"prefix":"10.1186","volume":"24","author":[{"given":"Ah Reum","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonse","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Joo","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soohyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"issue":"Suppl 3","key":"10859_CR1","doi-asserted-by":"publisher","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","volume":"25","author":"R Coleman","year":"2014","unstructured":"Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO Clinical Practice guidelines. Ann Oncol. 2014;25(Suppl 3):iii124\u201337.","journal-title":"Ann Oncol"},{"key":"10859_CR2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/annonc\/mdm442","volume":"19","author":"M Aapro","year":"2008","unstructured":"Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008;19:420\u201332.","journal-title":"Ann Oncol"},{"key":"10859_CR3","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","volume":"16","author":"GN Hortobagyi","year":"1998","unstructured":"Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 aredia breast Cancer Study Group. J Clin Oncol. 1998;16:2038\u201344.","journal-title":"J Clin Oncol"},{"key":"10859_CR4","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879\u201382.","journal-title":"J Natl Cancer Inst"},{"key":"10859_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003188.CD003188","author":"B Djulbegovic","year":"2002","unstructured":"Djulbegovic B, Wheatley K, Ross H, Clark O, Bos CA. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev. 2002. https:\/\/doi.org\/10.1002\/14651858.CD003188.CD003188.","journal-title":"Cochrane Database Syst Rev"},{"key":"10859_CR6","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377\u201387.","journal-title":"Cancer J"},{"key":"10859_CR7","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/cncr.20308","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613\u201321.","journal-title":"Cancer"},{"key":"10859_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, et al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on skeletal events in patients with bone metastases: a Randomized Clinical Trial. JAMA. 2017;317:48\u201358.","journal-title":"JAMA"},{"key":"10859_CR9","doi-asserted-by":"publisher","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","volume":"27","author":"K Vahtsevanos","year":"2009","unstructured":"Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009;27:5356\u201362.","journal-title":"J Clin Oncol"},{"key":"10859_CR10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","volume":"24","author":"AT Stopeck","year":"2016","unstructured":"Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016;24:447\u201355.","journal-title":"Support Care Cancer"},{"key":"10859_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","volume":"19","author":"WX Qi","year":"2014","unstructured":"Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014;19:403\u201310.","journal-title":"Int J Clin Oncol"},{"key":"10859_CR12","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1007\/s00520-019-04848-4","volume":"27","author":"CHL Hong","year":"2019","unstructured":"Hong CHL, Gueiros LA, Fulton JS, Cheng KKF, Kandwal A, Galiti D, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019;27:3949\u201367.","journal-title":"Support Care Cancer"},{"key":"10859_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jcms.2011.05.003","volume":"40","author":"S Otto","year":"2012","unstructured":"Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, St\u00fcrzenbaum S, et al. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg. 2012;40:303\u20139.","journal-title":"J Craniomaxillofac Surg"},{"key":"10859_CR14","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1200\/JCO.19.03148","volume":"38","author":"PJ Saylor","year":"2020","unstructured":"Saylor PJ, Rumble RB, Tagawa S, Eastham JA, Finelli A, Reddy PS, et al. Bone Health and Bone-targeted therapies for prostate Cancer: ASCO endorsement of a Cancer Care Ontario Guideline. J Clin Oncol. 2020;38:1736\u201343.","journal-title":"J Clin Oncol"},{"key":"10859_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1200\/JOP.19.00384","volume":"15","author":"CL Shapiro","year":"2019","unstructured":"Shapiro CL, Yarom N, Peterson DE, Bohlke K, Saunders DP. Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline summary. J Oncol Pract. 2019;15:603\u20136.","journal-title":"J Oncol Pract"},{"key":"10859_CR16","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1210\/jc.2015-1794","volume":"100","author":"IW Sim","year":"2015","unstructured":"Sim IW, Sanders KM, Borromeo GL, Seymour JF, Ebeling PR. Declining incidence of medication-related osteonecrosis of the Jaw in patients with Cancer. J Clin Endocrinol Metab. 2015;100:3887\u201393.","journal-title":"J Clin Endocrinol Metab"},{"key":"10859_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/JOP.18.00444","volume":"14","author":"S Leng","year":"2018","unstructured":"Leng S, Lentzsch S. Bone-modifying agents: complicated to Use. J Oncol Pract. 2018;14:469\u201370.","journal-title":"J Oncol Pract"},{"key":"10859_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10549-011-1429-y","volume":"127","author":"R Coleman","year":"2011","unstructured":"Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01\u201304) for women with stage II\/III breast cancer. Breast Cancer Res Treat. 2011;127:429\u201338.","journal-title":"Breast Cancer Res Treat"},{"key":"10859_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and maxillofacial surgeons\u2019 position paper on medication-related osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022;80:920\u201343.","journal-title":"J Oral Maxillofac Surg"},{"key":"10859_CR20","first-page":"e326","volume":"25","author":"A Limones","year":"2020","unstructured":"Limones A, S\u00e1ez-Alcaide LM, D\u00edaz-Parre\u00f1o SA, Helm A, Bornstein MM, Molinero-Mourelle P. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: a systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal. 2020;25:e326\u201336.","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10859_CR21","doi-asserted-by":"publisher","first-page":"5998","DOI":"10.3390\/ijerph17165998","volume":"17","author":"G Campisi","year":"2020","unstructured":"Campisi G, Mauceri R, Bertoldo F, Bettini G, Biasotto M, Colella G, et al. Medication-related osteonecrosis of Jaws (MRONJ) Prevention and diagnosis: Italian Consensus Update 2020. Int J Environ Res Public Health. 2020;17:5998.","journal-title":"Int J Environ Res Public Health"},{"key":"10859_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.oooo.2018.09.008","volume":"127","author":"O Nicolatou-Galitis","year":"2019","unstructured":"Nicolatou-Galitis O, Schi\u00f8dt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127:117\u201335.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10859_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CLEP.S37664","volume":"5","author":"J Bergdahl","year":"2013","unstructured":"Bergdahl J, Jarnbring F, Ehrenstein V, Gammelager H, Granath F, Kieler H, et al. Evaluation of an algorithm ascertaining cases of osteonecrosis of the jaw in the Swedish National Patient Register. Clin Epidemiol. 2013;5:1\u20137.","journal-title":"Clin Epidemiol"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-10859-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-024-10859-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-10859-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T20:26:03Z","timestamp":1712089563000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-024-10859-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["10859"],"URL":"https:\/\/doi.org\/10.1186\/s12913-024-10859-7","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,2]]},"assertion":[{"value":"27 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with relevant Korean guidelines and regulations. The study was approved by the Institutional Review Board of Korea University Anam Hospital (2020AN0012). The requirement for written informed consent was waived by the Institutional Review Board of Korea University Anam Hospital (2020AN0012). All procedures performed in the study are in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"412"}}